« on: January 03, 2012, 11:29:36 AM »
"We are pleased that the FDA was able to complete its review in approximately 60 days, enabling us to resume our limited commercial release of the AspireHC generator in the United States," said Dan Moore, Cyberonics' President and Chief Executive Officer. "With the CE Mark approval announced in December and a recently obtained Canadian approval, we will also resume the limited commercial release in Europe and initiate a limited commercial release in Canada. The AspireHC generator addresses a need among some patients for a device with a higher capacity battery and also provides a platform for the AspireSR™ seizure response generator, which is the subject of our E-36 clinical trial in Europe. We anticipate submission of the re-designed AspireSR generator for ethics committee and competent authority approvals for the E-36 clinical trial no later than the end of our fiscal year in April 2012."
« Reply #1 on: Today at 04:18:45 AM »